Effects of Neutralizing Antibodies or Antisera on Colony Formation by PB-Derived CD34+IL-6R+ CD34+IL-6R− Cells
| Factors . | Antibodies or Antisera . | Colony Types . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | G . | M . | GM . | B . | Eo . | E-Mix . | Total . |
| (A) CD34+IL-6R+ cells | ||||||||
| SCF + IL-3 | — | 7 ± 1 | 8 ± 1 | 3 ± 2 | 0 | 13 ± 2 | 0 | 32 ± 1 |
| SCF + IL-6 | — | 7 ± 1 | 3 ± 2 | 0 | 0 | 0 | 0 | 9 ± 1 |
| IL-3 + IL-6 | — | 0 | 11 ± 3 | 3 ± 2 | 0 | 18 ± 1 | 0 | 31 ± 2 |
| SCF + IL-3 + IL-6 | — | 18 ± 2 | 8 ± 2 | 5 ± 3 | 7 ± 2 | 11 ± 1 | 2 ± 1 | 51 ± 3 |
| Control sera3-150 | 19 ± 2 (NS) | 7 ± 4 | 6 ± 1 | 7 ± 2 | 11 ± 2 | 1 ± 0 | 51 ± 1 | |
| Anti–G-CSF serum3-151 | 21 ± 2 (NS) | 6 ± 2 | 4 ± 1 | 7 ± 2 | 12 ± 1 | 1 ± 1 | 51 ± 2 | |
| Anti–SCF Ab3-152 | 03-167 | 11 ± 2 | 3 ± 1 | 0 | 18 ± 2 | 0 | 32 ± 3 | |
| Anti–IL-3 serum3-151 | 5 ± 13-160 | 4 ± 1 | 0 | 0 | 0 | 0 | 9 ± 0 | |
| Anti–IL-6R Abρ | 6 ± 23-160 | 10 ± 1 | 3 ± 1 | 0 | 15 ± 2 | 0 | 34 ± 4 | |
| Anti–gp130 Abs3-155 | 8 ± 13-160 | 8 ± 4 | 4 ± 1 | 0 | 15 ± 3 | 0 | 34 ± 5 | |
| Combination of Abs3-154 | 03-167 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CSFs | — | 40 ± 2 | 12 ± 1 | 3 ± 1 | 41 ± 3 | 6 ± 2 | 3 ± 1 | 105 ± 3 |
| (B)CD34+IL-6R− cells | ||||||||
| SCF + IL-3 | — | 4 ± 1 | 5 ± 1 | 3 ± 2 | 0 | 12 ± 2 | 0 | 24 ± 1 |
| SCF + IL-6 + sIL-6R | — | 2 ± 1 | 4 ± 2 | 0 | 3 ± 1 | 0 | 2 ± 1 | 18 ± 2 |
| IL-3 + IL-6 + sIL-6R | — | 0 | 5 ± 2 | 3 ± 1 | 14 ± 1 | 3 ± 1 | 7 ± 1 | 32 ± 2 |
| SCF + IL-3 + IL-6 + sIL-6R | — | 5 ± 1 | 4 ± 1 | 3 ± 2 | 51 ± 3 | 4 ± 1 | 23 ± 1 | 90 ± 4 |
| Control sera | 5 ± 1 | 3 ± 2 | 2 ± 1 | 52 ± 2 (NS) | 4 ± 2 | 24 ± 1 | 87 ± 3 | |
| Anti-Epo Abρ | 4 ± 2 | 3 ± 2 | 4 ± 1 | 50 ± 2 (NS) | 3 ± 2 | 25 ± 1 | 89 ± 4 | |
| Anti-SCF Ab | 0 | 5 ± 1 | 3 ± 1 | 16 ± 13-160 | 4 ± 2 | 7 ± 2 | 33 ± 1 | |
| Anti–IL-3 serum | 2 ± 1 | 3 ± 1 | 0 | 1 ± 13-167 | 0 | 1 ± 1 | 7 ± 3 | |
| Anti–IL-6R Ab | 4 ± 2 | 6 ± 2 | 3 ± 1 | 03-167 | 12 ± 2 | 0 | 24 ± 4 | |
| Anti-gp130 Ab | 4 ± 2 | 5 ± 1 | 5 ± 2 | 03-167 | 13 ± 1 | 0 | 26 ± 3 | |
| Combination of Abs | 0 | 0 | 0 | 03-167 | 0 | 0 | 0 | |
| CSFs | — | 14 ± 2 | 6 ± 2 | 5 ± 2 | 60 ± 4 | 4 ± 2 | 18 ± 2 | 106 ± 1 |
| Factors . | Antibodies or Antisera . | Colony Types . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | G . | M . | GM . | B . | Eo . | E-Mix . | Total . |
| (A) CD34+IL-6R+ cells | ||||||||
| SCF + IL-3 | — | 7 ± 1 | 8 ± 1 | 3 ± 2 | 0 | 13 ± 2 | 0 | 32 ± 1 |
| SCF + IL-6 | — | 7 ± 1 | 3 ± 2 | 0 | 0 | 0 | 0 | 9 ± 1 |
| IL-3 + IL-6 | — | 0 | 11 ± 3 | 3 ± 2 | 0 | 18 ± 1 | 0 | 31 ± 2 |
| SCF + IL-3 + IL-6 | — | 18 ± 2 | 8 ± 2 | 5 ± 3 | 7 ± 2 | 11 ± 1 | 2 ± 1 | 51 ± 3 |
| Control sera3-150 | 19 ± 2 (NS) | 7 ± 4 | 6 ± 1 | 7 ± 2 | 11 ± 2 | 1 ± 0 | 51 ± 1 | |
| Anti–G-CSF serum3-151 | 21 ± 2 (NS) | 6 ± 2 | 4 ± 1 | 7 ± 2 | 12 ± 1 | 1 ± 1 | 51 ± 2 | |
| Anti–SCF Ab3-152 | 03-167 | 11 ± 2 | 3 ± 1 | 0 | 18 ± 2 | 0 | 32 ± 3 | |
| Anti–IL-3 serum3-151 | 5 ± 13-160 | 4 ± 1 | 0 | 0 | 0 | 0 | 9 ± 0 | |
| Anti–IL-6R Abρ | 6 ± 23-160 | 10 ± 1 | 3 ± 1 | 0 | 15 ± 2 | 0 | 34 ± 4 | |
| Anti–gp130 Abs3-155 | 8 ± 13-160 | 8 ± 4 | 4 ± 1 | 0 | 15 ± 3 | 0 | 34 ± 5 | |
| Combination of Abs3-154 | 03-167 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CSFs | — | 40 ± 2 | 12 ± 1 | 3 ± 1 | 41 ± 3 | 6 ± 2 | 3 ± 1 | 105 ± 3 |
| (B)CD34+IL-6R− cells | ||||||||
| SCF + IL-3 | — | 4 ± 1 | 5 ± 1 | 3 ± 2 | 0 | 12 ± 2 | 0 | 24 ± 1 |
| SCF + IL-6 + sIL-6R | — | 2 ± 1 | 4 ± 2 | 0 | 3 ± 1 | 0 | 2 ± 1 | 18 ± 2 |
| IL-3 + IL-6 + sIL-6R | — | 0 | 5 ± 2 | 3 ± 1 | 14 ± 1 | 3 ± 1 | 7 ± 1 | 32 ± 2 |
| SCF + IL-3 + IL-6 + sIL-6R | — | 5 ± 1 | 4 ± 1 | 3 ± 2 | 51 ± 3 | 4 ± 1 | 23 ± 1 | 90 ± 4 |
| Control sera | 5 ± 1 | 3 ± 2 | 2 ± 1 | 52 ± 2 (NS) | 4 ± 2 | 24 ± 1 | 87 ± 3 | |
| Anti-Epo Abρ | 4 ± 2 | 3 ± 2 | 4 ± 1 | 50 ± 2 (NS) | 3 ± 2 | 25 ± 1 | 89 ± 4 | |
| Anti-SCF Ab | 0 | 5 ± 1 | 3 ± 1 | 16 ± 13-160 | 4 ± 2 | 7 ± 2 | 33 ± 1 | |
| Anti–IL-3 serum | 2 ± 1 | 3 ± 1 | 0 | 1 ± 13-167 | 0 | 1 ± 1 | 7 ± 3 | |
| Anti–IL-6R Ab | 4 ± 2 | 6 ± 2 | 3 ± 1 | 03-167 | 12 ± 2 | 0 | 24 ± 4 | |
| Anti-gp130 Ab | 4 ± 2 | 5 ± 1 | 5 ± 2 | 03-167 | 13 ± 1 | 0 | 26 ± 3 | |
| Combination of Abs | 0 | 0 | 0 | 03-167 | 0 | 0 | 0 | |
| CSFs | — | 14 ± 2 | 6 ± 2 | 5 ± 2 | 60 ± 4 | 4 ± 2 | 18 ± 2 | 106 ± 1 |
Data represent the mean ± SD of triplicate cultures containing 200 cells/dish with the specified factors and 30% FCS. Abbreviations are defined in the legend for Table 1.
Normal mouse serum + normal rabbit serum.
(1:100) dilution.
20 μg/mL.
ρ 5 μg/mL.
Combination of three anti-gp130 Abs (GPX-7, GPX-22, and GPZ-35) at 1 μg/mL each.
Anti-SCF Ab + anti–IL-3 serum + anti–IL-6R Ab + anti-gp130 Abs.
P < .001.
P < .01.